Modeling Multiple Sclerosis in the Two Sexes: MOG<sub>35-55</sub>-Induced Experimental Autoimmune Encephalomyelitis

Brigitta Bonaldo; Antonino Casile; Francesca Montarolo; Antonio Bertolotto

doi:10.3791/65778

JoVE Journal > Neuroscience

神经科学

Modeling Multiple Sclerosis in the Two Sexes: MOG_35-55-Induced Experimental Autoimmune Encephalomyelitis

Published: October 13, 2023

doi:

10.3791/65778

Brigitta Bonaldo^1,2, Antonino Casile^1,2,3, Francesca Montarolo^1,2, Antonio Bertolotto^1,4

¹Neuroscience Institute Cavalieri Ottolenghi (NICO), ²Department of Neuroscience “Rita Levi-Montalcini”,University of Turin, ³School of Pharmacy, Pharmacology Unit,University of Camerino, ⁴Koelliker Hospital

Summary

Experimental autoimmune encephalomyelitis is one of the most widely used murine models of multiple sclerosis. In the current protocol, C57BL/6J mice of both sexes are immunized with myelin oligodendrocyte glycoprotein peptide, resulting mainly in ascending paresis of the tail and limbs. Here we discuss the protocol of EAE induction and evaluation.

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It is characterized by different prevalence in the sexes, affecting more women than men, and different outcomes, showing more aggressive forms in men than in women. Furthermore, MS is highly heterogeneous in terms of clinical aspects, radiological, and pathological features. Thus, it is necessary to take advantage of experimental animal models that allow the investigation of as many aspects of the pathology as possible. Experimental autoimmune encephalomyelitis (EAE) represents one of the most used models of MS in mice, modeling different disease features, from the activation of the immune system to CNS damage. Here we describe a protocol for the induction of EAE in both male and female C57BL/6J mice using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG_35-55) immunization, which leads to the development of a chronic form of the disease. We also report the evaluation of the daily clinical score and motor performance of these mice for 28 days post immunization (28 dpi). Lastly, we illustrate some basic histological analysis at the CNS level, focusing on the spinal cord as the primary site of disease-induced damage.

Introduction

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It shows the presence of perivascular infiltration of inflammatory cells, demyelination, axonal loss, and gliosis¹. Its etiology remains unknown, and its clinical aspects, radiographic, and pathological features suggest remarkable heterogeneity in the disease².

Due to its unknown etiology and complexity, at present, no animal model recapitulates all the clinical and radiological features displayed in human MS³^,⁴. However, various animal models are employed to study different aspects of MS³^,⁴. In these models, disease initiation is typically extremely artificial, and the timeframe of the onset of clinical signs is different between humans and mice. For example, in humans, the pathophysiological processes underlying the disease are undetected for years before the onset of clinical manifestations. Conversely, the experimenters can detect symptoms in animal models within weeks or even days after MS induction⁴.

Three basic animal models produce the features of demyelination that are characteristic of MS: those that are virus-induced (e.g., Theiler's murine encephalomyelitis virus), those that are induced by toxic agents (e.g., cuprizone, lysolecithin), and the different variants of experimental autoimmune encephalomyelitis (EAE)⁵. Each model helps study some specific facets of the disease but none replicates all the features of MS⁶. Thus, it is critical to choose the correct model considering the specific experimental needs and the scientific questions to be addressed.

Thanks to immunization procedures against myelin-derived antigens, EAE is induced by triggering an autoimmune response to CNS components in susceptible mice. The interplay between a wide range of immunopathological and neuropathological mechanisms causes the development of principal pathological traits of MS (i.e., inflammation, demyelination, axonal loss, and gliosis) in the immunized mice⁷^,⁸. Mice begin to show clinical symptoms around the second week after immunization and generally show ascending paralysis from the tail to the limb and forelimb. The clinical score (i.e., quantification of the accumulation of disease-related deficits) is generally assessed using a 5-point scale⁷.

Active immunization with protein or peptide or passive transfer of encephalitogenic T cells can be used to induce EAE in mice with different genetic backgrounds (e.g., SJL/J, C57BL/6, and non-obese-diabetic (NOD) mice). Myelin proteolipid protein (PLP), myelin basic protein (MBP), and myelin oligodendrocyte glycoprotein (MOG) are examples of self-CNS proteins from which immunogens are usually produced. Particularly, SJL/J mice immunized with the immunodominant epitope of PLP (PLP₁₃₉₋₁₅₁) develop a relapsing-remitting (RR) disease course, while C57BL/6J mice immunized with the immunodominant MOG_35-55peptide show EAE of a chronic nature¹. Despite some limitations, such as providing very little information about MS progression, the role of B cells in the disease, the inside-out mechanisms, or difficulties in studying remyelination, the EAE models have hugely contributed to the understanding of autoimmune and neuroinflammatory processes, increasing the knowledge in the MS field and thus allowing the development of novel therapeutic approaches for this disease⁴^,⁶.

In the present work, we focused on a particular form of active EAE, the myelin oligodendrocyte glycoprotein peptide 35-55 (MOG_35-55)-induced form⁹^,¹⁰^,¹¹^,¹². The MOG_35-55-induced EAE models a chronic form of MS. After immunization, the mice undergo an asymptomatic phase within the first week after immunization, then the disease typically arises during the second week after immunization, while between the third and fourth weeks after immunization, the disease becomes chronic, with no possibility of full recovery from the accumulated deficits⁷^,⁸^,¹³. Interestingly, no differences between males and females in incidence, disease onset, course, or progression are observed in most of the studies present in the literature¹⁴, even if fewer studies compare the disease in males and females.

In contrast, in humans, these parameters are known to be strongly sexually dimorphic². MS affects more women than men; however, men generally develop a more aggressive form of the disease². This evidence has suggested an essential, as well as complex, role of the gonadal hormones¹⁵; nevertheless, the role and the mechanism of action of sex hormones in the pathology remain unclear. Moreover, data from animal models support the idea that both estrogens and androgens exert positive effects on different tracts of the pathology in a sex-specific manner¹⁶^,¹⁷.

Some studies also suggest neuroprotective, promyelinating, and anti-inflammatory effects of progesterone¹⁸ and, although evidence in MS patients is scarce¹⁸, neuroactive steroids (i.e., de novo synthetized steroids by the nervous system, such as pregnenolone, tetrahydroprogesterone, and dihydroprogesterone) might also affect the pathological course¹⁹. Collectively, these data support the idea that sex hormones produced both peripherally and inside the CNS have an important and sex-specific role in disease onset and progression. Therefore, in the present work, we urge the collection of separate data from both male and female animals.

From the histopathological point of view, the white matter of the spinal cord serves as the principal site of CNS injury in this model, which is characterized by multifocal, confluent regions of mononuclear inflammatory infiltration and demyelination⁸. Thus, in describing this protocol for the induction of MOG_35-55-induced EAE in C57BL/6J mice, we will take into account the disease outcome in the two sexes and provide some histopathological insights regarding the spinal cords.

Protocol

The animal care and handling in the present work was performed according to the European Union Council Directive of 22^nd September 2010 (2010/63/UE); all the procedures reported in the present study were approved by the Italian Ministry of Health (407/2018-PR) and by the Ethical Committee of the University of Torino (Project n° 360384). We suggest conforming to the experimental design to the ARRIVE guidelines originally published by Kilkenny et al. in 2010²⁰. Before starting, ensure that the necessary materials are available (see Table of Materials). Sterilize all glassware and utensils used for the preparation of the MOG_35-55emulsion in an autoclave. A summary of the experimental procedures is represented in Figure 1.

1. Preparation of MOG_35-55 emulsion

NOTE: To prepare the emulsion, MOG_35-55, incomplete Freud's adjuvant (IFA), Mycobacterium Tuberculosis strain H37Ra (MT), and physiological solution are required (see Table of Materials).

CAUTION: Heat-killed MT can stimulate the innate immune response. Avoid inhalation, ingestion, and contact with skin and eyes using proper personal protective equipment and weighing MT in a covered precision balance under the hood.

Solution	Composition	Notes
2 mg/mL MOG_35-55peptide solution	Lyophilized MOG35-55 peptide diluted in physiological solution at 2 mg/mL concentration	Preserve the already diluted solution at -80 °C.
5 µg/mL PT solution	Lyophilized PT diluted in physiological solution at 5 µg/mL concentration.	Preserve the already diluted solution at -80 °C.
Emulsion	The total volume of emulsion needed for each mouse to be immunized is 300 µL divided as follows:	To avoid alteraions or contamination, prepare the emulsion the day of the immunization.
	200 µg/mouse of MOG_35-55, i.e., 100 µL of MOG_35-552 mg/mL solution.
	50 µL of physiological solution
	150 µL of IFA
	4 mg/mL MT, i.e., 1.2 mg/mouse
Physiological solution	Sodium chloride 0.9% diluted in distilled water.

Table 1: Composition of the solutions used for the immunization procedure.

Prepare the solution in a glass beaker, adding the liquid component first and finally the MT.
NOTE: The total volume of emulsion needed for each mouse to be immunized is 300 µL, divided as indicated in Table 1. The emulsion is very viscous and thick, so during the preparation and injection procedure, there could be some loss, especially when preparing the solution for a few mice. We suggest calculating the final volume of emulsion needed by overestimating the number of mice to be immunized by at least 1.5-2-fold.
Place the beaker in ice and use the glass syringe with an 18 G needle to start emulsifying the solution.
NOTE: The emulsion can also be prepared using other strategies, for example, by connecting the two air-free glass syringes with a three-way stopcock and mixing the solution by pushing the plungers back and forth²¹^,²².
Emulsify the solution for at least 15 min; generally, 30 min of emulsification is enough. To check the quality of the emulsion, add a drop of emulsion in a transparent container filled with water: if the drop maintains its structure and remains intact, the emulsion is ready.
Place the emulsion directly inside the 1 mL syringes that will be used for the immunization and store these at +4 °C until use to preserve the thickness of the emulsion and avoid alterations or contaminations.

2. Animal selection and immunization

Animal selection
1. Select adult C57BL/6J mice of both sexes at 8-10 weeks of age with an optimal body weight of ~20 g. Be sure to select age- and sex-matched mice for different experimental groups because the susceptibility to disease can vary with age and sex.
  NOTE: Mice should be of comparable body weight on the day of immunization because the present procedure is optimized for a certain body weight range (17-25 g).
2. House same-sex animals in groups (n = 4-5/cage) to avoid social isolation in standard conditions in 45 cm x 25 cm x 15 cm polypropylene mouse cages at 22 ± 2 °C, under 12:12 light/dark cycle (lights on at 08:00 AM). Provide food and water ad libitum.
  NOTE: Eventually, to further limit the potential variability of disease course in the immunized animals, we also suggest forming sufficiently numerous experimental groups. There are also studies⁸^,²³ that describe the timing of immunization as a condition that determines variation in EAE outcome. Thus, we suggest performing the immunization approximately at the same hour in all animals, preferably during the light hours of the daily light/dark cycle²³. To limit stress, it is preferable to manipulate the animals prior to the day of immunization and to mark them to easily identify them for daily evaluation, for example, ear clipping or tag.
The immunization procedure
NOTE: Ensure that the procedure is performed by an experienced investigator to minimize stress for animals and optimize immunization. Before starting the immunization, select the anesthesia method in accordance with the institutional animal care and ethical committee guidelines. Our laboratory uses brief anesthesia with isoflurane.
1. Anesthetize the mouse: 4% isoflurane for anesthesia induction and 1.5-2% isoflurane for anesthesia maintenance. Wait for the anesthesia to be effective and use a back and front foot toe pinch to assess the level of anesthesia. To prevent dryness of the eyes while the mouse is under anesthesia, use a vet-approved eye ointment.
2. PT intravenous injection in the lateral caudal vein: plug the tail of the mouse gently with an ethanol solution, which acts as a vasodilator, to display the veins. Focus on one of the two lateral veins of the tail, and, using a 0.5 mL syringe fitted with a 30 G needle, inject 500 ng of PT (i.e., 100 µL of PT diluted in physiological solution at the concentration of 5 µg/mL).
3. Subcutaneous injection of MOG_35-55emulsion: using the 1 mL syringe with a 26 G needle, perform three subcutaneous injections of the previously prepared emulsion: two under the rostral part of the flanks and one at the base of the tail. The volume of emulsion injected in each site is 100 µL, for a total volume of 300 µL of emulsion injected in each mouse.
  NOTE: The day of immunization is recorded as day 0 post immunization (dpi); 48 h later (i.e., at 2 dpi), it is necessary to perform another intravenous injection of PT equal to the one previously performed. It is possible to perform the injection without anesthesia, using a mouse restrainer. The procedure described here aims to induce and maintain anesthetizing of the mice during the immunization procedure to avoid possible discomfort and movements of the animals or risks for both mice and investigators. Thus, there are no surgical procedures. However, to optimize the experimental processes, it is important to maintain appropriate sterile conditions during these steps and to monitor the mouse's condition after these procedures.
4. To verify the mouse has recovered from the injections, place it in a clean cage after the procedures and wait until it has regained sufficient consciousness to maintain sternal recumbency. After the mouse has fully recovered, return it to the home cage with other animals.

3. EAE follow-up

Body weight and food intake
1. Monitor daily the body weight (BW) of the animals, using an electronic precision balance, because the decrease in BW is an indicator of disease progression.
  NOTE: This decrease should not exceed a certain percentage, according to the institutional and ethical committee's guidelines for animal care. Usually, if an animal loses more than 20% of the initial body weight (i.e., the weight recorded at 0 dpi), it should be sacrificed as the application of the humane endpoint. The euthanasia methods involve deep irreversible anesthesia for inhalation (e.g., 5% isoflurane) followed by decapitation.
2. Monitor the food intake (FI)-the food eaten by an animal in a day (g∙day^-1∙animal^-1), weighing the amount of food in the specific container at least once a week, and dividing the amount of eaten food for the days passed between two sequential measurements and the number of animals present in the cage.
  NOTE: This measurement allows the estimation of mean food intake. Because of the appearance and accumulation of clinical disease signs, which involve the paralysis of the limbs, we suggest placing some watered food on the floor of the cage when the animals are not capable of standing firmly on their hind limbs and reaching the food container or the water bottle. To assess the food intake through the follow-up period as precisely as possible, we also measured the dry weight of this food before wetting it for the mice.
Evaluation of estrous cyclicity during EAE
1. Check the estrous cycle for at least two cycles, evaluating the vaginal cytology smears as described by McLean et al.²⁴. Classify the phase of the estrous cycle based on the presence of three primary cell types-nucleated epithelial cells, cornified squamous epithelial cells, and leukocytes-in the vaginal smear samples, as follows:
  1. Classify as proestrus based on an almost exclusive presence of clusters of round, well-formed nucleated epithelial cells.
  2. Classify as estrus based on the predominant presence of densely packed clusters of cornified squamous epithelial cells.
  3. Classify as metestrus based on the predominant presence of small darkly stained leukocytes and the minor presence of cornified squamous epithelial cells.
  4. Classify as diestrus based on the highly predominant presence of small darkly stained leukocytes and rare cornified squamous epithelial cells along with the possible appearance of nucleated epithelial cells.
    NOTE: When evaluating the disease in both sexes, it is important to check the variability in females due to the estrous cycle. We suggest focusing on the evaluation of the estrous cycle, especially between the first and the second-week post immunization (i.e., during the acute phase of the EAE). It has been previously shown that the immunization procedure causes the most pronounced alterations of the estrous cycle within this phase²⁵. Moreover, it is important to consider that performing the smear when the animal reaches a high clinical score (especially >3) is difficult due to the posterior paresis and the lack of tone in the hindlimbs.
Clinical score
1. Have a blinded investigator assess the clinical score of the animals daily. Assign to each animal a score rated from 0 to 5 (see Table 2) to evaluate the disease course²⁶ as described by Racke⁷.
  NOTE: Similar to the body weight decrease, a humane endpoint is also necessary for the increase in clinical scores, according to the institutional and ethical committee's guidelines for animal care. Generally, if an animal is no longer able to feed itself autonomously (this usually occurs when an animal reaches at least the score of 4, according to the scale we use), it should be sacrificed as the application of the humane endpoint.
Motor performance evaluation by rotarod test
NOTE: Evaluation of the EAE progression is usually performed by assigning the clinical score daily, which is done by a fully trained blinded investigator. However, it could be useful to flank it with a more quantitative and objective evaluation of the disease's progression. In a previous study²⁶, the rotarod test was used to measure the motor performance of the immunized animals. As described by van den Berg et al.²⁷, to have a more quantitative and precise clinical evaluation of the disease course, the evaluation of the motor performance by the rotarod test can support the clinical score assessment. For a detailed description, see van den Berg et al.²⁷.
1. Let the mice undergo rotarod sessions daily, starting from 1 dpi until the sacrifice (i.e., 28 dpi). Each session consists of a single 300 s session during which the rod speed has to be increased linearly from 4 to 40 rpm.
2. Register the animal's score. When the mouse is not capable of maintaining its balance and falls off the device, it falls on the ground and triggers a sensor, and the time (s) is recorded. Thus, the performance is scored as latency to fall (s).

Grade	Clinical sign	Description
0	Healthy	No observed clinical sign. The animal shows a normal tone and moving of the tail. It walks without tripping.
0.5	Impaired gate	The animal trips while walking on a grill.
1	Limp tail	When the animal is picked up by the basis of the tail, the tail droops (flabby tail).
1.5	Limp tail and impaired gate	The animal shows a flabby tail, and it trips while walking on a grill.
2	Ataxia	The animal displays difficulties in standing up once it has been turned on its back.
2.5	Ataxia and paresis of hindlimb	The animal displays cannot stand up once it has been turned on its back, and it loses the tone of one of its hindlimbs.
3	Paralysis of hindlimbs	The animal loses the tone of both hindlimbs.
3.5	Paralysis of hindlimbs and/or paresis of forelimb	The animal loses the tone of both hindlimbs and partially of forelimbs. In fact, it shows a loss of strength in the forelimbs’ grasp.
4	Tetra paresis	The animal completely loses the tone of its limbs.
4.5	Tetra paresis and decreased body temperature	The animal completely loses the tone of its limbs, and it shows a decrease in body temperature (it is cold).
5	Dying or dead	The animal is dying (it does not respond to any stimulus) or dead.

Table 2: Clinical scoring system used to assess EAE progression.

4. Evaluation of EAE-induced histopathological signs at the spinal cord level

NOTE: Here, we briefly report the procedure to sacrifice the animals and collect the spinal cords to perform histopathological analysis; for a detailed description, see these references¹⁰^,²⁶^,²⁸^,²⁹.

Fixation and tissue sampling
NOTE: For a detailed description, see these references¹⁰^,²⁶.
1. Sacrifice the animals at 28 dpi during the chronic phase of the disease.
  1. Anesthetize the mice by deep irreversible anesthesia (intraperitoneal injection of Zolazepam and Tiletamine 80 mg/kg / Xylazine 10 mg/kg).
  2. Transcardially perfuse the mice with a saline solution followed by a 4% paraformaldehyde (PFA) solution.
    NOTE: Pay attention while using PFA: as it is toxic, avoid inhalation, ingestion, and contact with skin and eyes using proper personal protective equipment. Weigh the powder, prepare the solution, and perform the perfusion under the hood.
2. Remove the spinal cords from the spinal column³⁰.
3. Store the spinal cords in a 4% PFA solution for 24 h.
4. Perform several washes in 0.01 M saline phosphate buffer (PBS).
5. Embed the spinal cords in paraffin blocks³⁰.
Histological procedures
NOTE: For a detailed description, see Montarolo et al.¹⁰.
1. Use a microtome to cut 10 µm thick transverse spinal cord sections and collect them on gelatin-coated slides. Orient the plane of sectioning to match the drawings corresponding to the transverse sections of the mouse spinal cord atlas³¹.
2. Perform the deparaffinization of the sections³².
3. Stain the section with Hematoxylin and Eosin³².
4. Dehydrate the sections³².
5. Cover the sections with a mounting medium and let them dry at room temperature under a chemical hood.
  NOTE: Hematoxylin-Eosin staining allows for the detection of the presence of the perivascular inflammatory infiltrates (PvIIs)²⁶, which is assessed as a sign of the disease²⁸.
Quantitative analysis of spinal cord sections
1. Acquire images of the stained sections with an optical microscope connected to a digital camera with a 20x objective²⁹.
2. Analyze the acquired image to obtain the number of PvIIs, expressed as the number of infiltrates per mm².
  NOTE: For the analysis of the acquired images, it is useful to take advantage of image analysis software. Neuropathological findings presented in this work are quantified in 10 complete cross-sections of the spinal cord per mouse (n = 8/group) representative of whole spinal cord levels.

Representative Results

EAE follow-up after immunization
This was assessed as described below.

Body weight and food intake
The two-way analysis of variance (ANOVA) (sex and time as independent variables) shows a decrease in the BW of EAE animals of both sexes, especially within the second week post induction (F_(1,57)= 4.952, p < 0.001; Figure 2A). However, the sexual dimorphism in BW is always maintained (Figure 2A). In terms of the percentage of BW (F_(1,57)= 23.935, p < 0.001; Figure 2B), both males and females display a huge loss between the 12 dpi to the 17 dpi (p < 0.001) compared to the initial BW but never exceed a total loss of the 20% (Figure 2B). Thus, although the BW loss starts before the onset of the disease, it reaches its maximum during the acute phase of EAE (Figure 2A,B). There are no differences between the sexes in terms of BW loss. However, females tend to lose more weight earlier and recover less during the chronic phase (third-fourth week post induction) (Figure 2B).

Moreover, the two-way ANOVA (sex and time as independent variables) also shows a significant decrease in FI (F_{(9, 39)}= 6.682, p < 0.001; Figure 2C) in both sexes, particularly during the second post-immunization week, as a result of increased EAE severity, which made it more challenging for the animal to access the food placed in the upper container in the cage. As we suggested, the food was subsequently put on the cage floor to reduce further stress on the animals. This allowed the FI to return to initial levels (Figure 2C), and the BW to partially recover (Figure 2A,B).

Estrous cycle evaluation in the females
The comparison between the time spent in the different phases of the estrous was performed using the Student's t-test. The analysis shows differences in the time spent in the estral phases (i.e., proestrus and estrus) compared to that spent in the non-estral phase (i.e., metestrus and diestrus) between the asymptomatic phase (prior to the onset of the EAE) and the symptomatic phase (after the onset of the EAE) (p = 0.042; Figure 2D), mainly due to an increase in the time spent in diestrus during the symptomatic phases (p = 0.017) and a tendency in reducing time spent in proestrus (p = 0.08).

It has already been described that the induction procedure leads to an alteration of the estrous cycle in females, particularly affecting the proestrus²⁵. During this phase, increasing levels of estrogens are known to exert anti-inflammatory and neuroprotective effects¹⁶ and thus, are possibly responsible for the protective role of those hormones during the presymptomatic phase. However, when the level of estrogens drops, as we see in the post onset phase, their protective effects also end.

Clinical score and rotarod performance
The two-way ANOVA (sex and time as independent variables) shows a significant increase in time in the clinical score (CS) of both males and females (F_(56-813)= 27.951, p < 0.001; Figure 3A). In particular, starting from 10 dpi, both sexes show a significant increase in the CS (p < 0.001), which is maintained until the endpoint (28 dpi) (Figure 3A). Females display, even if not significantly (p = 0.156), higher CS than males (Figure 3A). In terms of disease onset, it occurs generally around 10 dpi, with a tendency for earlier onset in females than in males (Figure 3B). Furthermore, females show a significative higher cumulative CS compared to males (p = 0.017; Figure 3C).

The rotarod performance course resembles the clinical evaluations (Figure 2D). Starting from the onset of the disease, it decreases, reaching the minimum performance during the second week post immunization, in the acute phase of EAE. The two-way ANOVA (sex and time as independent variables) shows a significant decrease in time in the rotarod performance of both males and females (F_(46-673)= 5.365, p < 0.001; Figure 3D). Particularly, males display the minimum performance at 16 dpi (p = 0.022) while the females at 17 dpi (p < 0.001). Males tend to perform better than females, especially during the chronic phase of the disease (21-28 dpi), possibly as a consequence of lower CS (Figure 3A,D).

Histopathological evaluation of the spinal cord
One-way ANOVA (sex as the independent variable) of the PvIIs in the spinal cord sections highlights a clear difference between males and females (Figure 4A). Females show a significantly higher number of PvIIs than males (F_(1,14)_{= 63.107,}p < 0.001; Figure 4B). These data possibly reflect the higher cumulative CS, the worse rotarod performance, and the more aggressive disease observed in the females, especially during the chronic phase of EAE.

These data also reflect the fact that female mice display higher susceptibility to the development of more aggressive EAE compared to males¹⁴, which is one of the main differences between this disease model and the MS that occurs in humans. Women display an earlier disease onset, have a moderately lower prevalence of primary progressive forms, and show overall less disability progression than men²^,³³^,³⁴.

Figure 1: Schematic temporal representation of experimental procedures. Created with BioRender.com. Abbreviations: i.v. = intravenous; s.c. = subcutaneous; MOG_35-55 = myelin oligodendrocyte glycoprotein peptide 35-55; = dpi = day post immunization. Please click here to view a larger version of this figure.

Figure 2: Evaluation of the EAE effects on body weight, food intake in male and female mice, and estrous cycle in female mice. From the day of immunization (0 dpi) until the day of the sacrifice (28 dpi), the graphs show (A) daily body weight, (B) percentage of body weight, and (C) weekly food intake evaluation in the animals of both sexes (n = 15/group). (D) Time spent (expressed as mean percentage of time) in the different phases of the estrous cycle, evaluated by vaginal cytology smears, during the asymptomatic phase (pre-onset, left column of the graph) or the symptomatic phase (post-onset, right column of the graph) in female mice. Data are presented as mean ± SEM. Statistical analysis revealed a significant effect for p≤ 0.05 (# = males vs. females; * = comparison between different time points). Abbreviations: EAE = experimental autoimmune encephalomyelitis; BW = body weight; FI = food intake; dpi = day post immunization. Please click here to view a larger version of this figure.

Figure 3: Evaluation of the clinical score and rotarod performance in EAE-affected male and female mice. (A) Assessment of daily clinical score (from 0 to 28 dpi) in the animals of both sexes (n = 15/group). (B) Day of disease onset (mean dpi) in EAE-affected males (left column) and females (right column) mice. (C) Mean cumulative clinical score reached by EAE-affected males (left column) and females (right column) mice. (D) Assessment of daily rotarod performance (measured as latency of fall) from 6 to 28 dpi (the 0 represents the baseline values obtained within the first 5 days of the test) in the animals of both sexes. Data is presented as mean ± SEM. Statistical analysis revealed a significant effect for p≤ 0.05 (# = males vs. females; * = comparison between different time points). Abbreviations: EAE = experimental autoimmune encephalomyelitis; CS = clinical score; Cum CS = cumulative clinical score; dpi = day post immunization. Please click here to view a larger version of this figure.

Figure 4: Analysis of inflammation in the spinal cord of EAE-affected mice of both sexes. (A) Representative images of transverse spinal cord sections stained with Hematoxylin-Eosin highlight the presence of PvIIs (arrows) in male (upper image) and female (lower image) mice. (B) Measure of PvIIs' presence in the spinal cord of EAE-affected mice of both sexes (n = 8/group). Data is presented as mean ± SEM. Statistical analysis revealed a significant effect for p ≤ 0.05 (# = males vs. females). Scale bar = 200 µm (10x magnification). Abbreviations: EAE = experimental autoimmune encephalomyelitis; * = central canal; PvIIs = perivascular inflammatory infiltrates. Please click here to view a larger version of this figure.

Discussion

The MOG_35-55-induced EAE protocol that we described led to the development of a chronic form of MS in C57BL/6J mice⁷^,⁸^,¹³. In these representative results, we reported that the animals of both sexes that underwent the immunization procedure developed a chronic form of the disease (i.e., they do not fully recover after the disease onset, they accumulate deficits, and maintain a CS at least of 1.5 in the chronic phase).

Even if many studies report no differences between males and females in this model¹⁴, only a few studies consider both sexes. However, given the substantial sexual dimorphisms displayed in MS², it should be of primary relevance to study the disease outcome in the two sexes. Thanks to more recent studies that include both sexes, the presence of some sexual dimorphism has also been described in the MOG_35-55-induced EAE³⁵. We mainly noticed that in females, MOG_35-55-induced EAE is generally more aggressive (given the higher susceptibility of female mice with this model)³⁶, as they tend to have earlier onset and higher cumulative clinical scores, which reflects increased inflammation at the spinal cord level than that observed in males. One major conclusion is that this protocol can induce EAE in both male and female mice, but investigators must remember that some aspects of the disease could differ between the two sexes. Thus, it is critical to properly consider the main experimental question to be addressed, to choose the most favorable animal model, and to evaluate the necessity to include either one or both sexes.

Critical steps and possible troubleshooting
As different models of MS produce some specific aspects of the disease, but not all⁶, the first fundamental step is to choose the correct model considering the specific experimental needs and the scientific questions to be addressed. Second, the immunization procedure should be performed by an expert to ensure it is done correctly and avoid errors or variability due to imprecise procedures. Additionally, the investigator must be aware of the animal welfare regulations adopted by the host institution.

Third, the emulsion should be standardized in the experiment. It should be noted that every mouse displays a typical susceptibility to the induction, and thus, some animals could develop a less aggressive disease or not develop it at all. In that case, the disease incidence and severity can be optimized by adjusting the quantity of MOG_35-55administered to the mice. Fourth, although PT injection is widely used to facilitate the induction of EAE in mice³⁵^,³⁶, it is not necessary for every protocol³⁷^,³⁸. In the absence of PT, mice usually develop a less severe and more variable form of EAE³⁹. Moreover, further variability can be caused by different ways of PT administration (e.g., intravenous vs. intraperitoneal) and because the potency of PT has been described to vary among batches. To overcome this issue, it is important to adjust the volume according to the potency of each batch used and to prepare the PT solution properly⁴⁰^,⁴¹. Considering the experimental goals, the investigators' technical skills, and the optimization of animal research, it is fundamental to choose the most suitable protocol of induction.

Fifth, to collect data in a more objective way, the blinded scoring of disease symptoms is highly recommended. Furthermore, we suggest clinical scoring with a more quantitative and objective evaluation of the disease course, such as the evaluation of the rotarod performance. Finally, the correct selection of adequately numerous experimental groups is fundamental to obtaining reliable and comparable data (see protocol section 2). Sample size calculations should be performed to obtain the necessary group sizes, depending on the expected effect size.

Main limitations
First, this protocol of induction could lead to highly variable outcomes in the immunized animals, especially if the group sizes are not large enough or if the procedure is not carried out properly. Next, MOG_35-55-induced EAE, like every other available model of MS, has some limitations (i.e., it provides very little information about MS progression, the role of B cells in the disease, the inside-out mechanisms, or difficulties in studying remyelination)⁴^,⁶. Hence, once again, it is fundamental to choose properly the MS model needed to address the specific scientific question. Finally, the primary site of damage is represented by the spinal cord, and the pathology leads to the appearance of histopathological signs in a caudal-cranial way (i.e., starting from the spinal cord and going up to the brain). This is the opposite of what occurs in humans and may represent a considerable limitation of the model. However, it is possible to also appreciate some alterations in the brain, considering specific targets.

Advantages
First, this model can significantly contribute to the understanding of peripheral immune-mediated mechanisms and to evaluate the neuroinflammatory and, partially, demyelinating processes in the CNS. Next, this model could be applied in some specific transgenic mouse strains to study MS outcomes related to specific genetic alterations.

Another advantage is having a clinical evaluation based on two methods: the clinical score assessment and the rotarod test. This leads to a more quantitative, less subjective, and more precise clinical evaluation of the disease course. Furthermore, as van den Berg et al. pointed out, the rotarod-based evaluation is strongly correlated to the surface area of inflammatory lesions in the motor systems of the spinal cord²⁷.

As we discussed earlier, even though this model does not entirely reproduce the sexual dimorphism of MS, we believe this to be an advantage. The combination of the induction with other possible risk factors, especially the environmental ones, can aid in understanding the specific effects of such factors and identifying their specific role in the occurrence of some sexually dimorphic aspects of MS. Finally, this model has been widely used to develop and test a wide range of therapeutic drugs and therefore, has potential to help develop new therapeutical approaches for this disease⁴^,⁶.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work has been supported by Ministero dell'Istruzione, dell'Università e della Ricerca – MIUR project Dipartimenti di Eccellenza 2018-2022 and 2023-2027 to Department of Neuroscience Rita Levi Montalcini; Cavalieri-Ottolenghi Foundation, Orbassano, Italy. BB was fellow of INFRA-P, Piedmont Region (n.378-35) (2022-2023) and PRIN 2020 – 20203AMKTW. We thank Fondazione per la Ricerca Biomedica Onlus (FORB) for the support. The publication fees have been supported by the kind donation of Distretto Rotaract 2031, and particularly, Rotaract Club Torino Nord-Est. We thank Elaine Miller for the proofreading of our manuscript.

Materials

18 G x 1 ½“ 1.2 x 40 mm needle for the glass syringe	Terumo	TER-HYP-18G-112-PIN
Digital camera connected to the optical microscope	NIKON DS-U1 digital camera
Electronic precision balance	Merck	Mod. Kern-440-47N, resolution 0.1 g
Eosin Y	Sigma-Aldrich	HT110216
Glass syringe pipet “ultra asept” 10 ml	Sacco System	L003465
Glassware (i.e., becker to prepare the emulsion)	VWR	213-1170, 213-1172
Hematoxylin (Mayer’s)	Sigma-Aldrich	MHS32	Filter before using it.
Image analysis Software	Fiji
Incomplete Freund’s adjuvant (IFA)	Sigma-Aldrich	F5506	Store at +4 °C.
Isoflurane	Wellona Pharma		This drug is used as inhalational anaesthetic.
Male and female C57BL/6J mice	Jackson Laboratory, Envigo		Age 8-10 weeks, optimal body weight of ~20 g.
Microtome	Leica HistoCore BIOCUT R
Mounting Medium	Merck	107961
Mouse Rotarod	Ugo Basile	#47600
Mycobacterium tuberculosis (MT), strain H37Ra	Difco Laboratories Inc.	231141	Store at +4 °C.
Myelin oligodendrocyte glycoprotein peptide 35-55 (MOG_35-55)	Espikem	EPK1	Store at -80 °C diluted (2 mg/mL) in physiological solution; prepare it on the day of the immunization to avoid, as much as possible, alterations or contaminations.
Optical microscope	NIKON eclipse 90i
Paraformaldehyde (PFA)	Sigma-Aldrich	158127	Store at +4 °C once diluted (4%) in phosphate buffer.
Pertussis toxin (PT)	Duotech	PT.181	Store at -80°C diluted (concentration 5 µg/mL) in physiological solution
Physiological solution (sodium chloride 0.9% solution)	B. Eurospital	A 032182038	Store at +4 °C once opened.
Saline phosphate buffer (PBS)	Thermo Scientific	J61196.AP
Software for image acquisition	NIS-Element AR 2.10
Syringes U-100 0.5 mL with 30 G x 5/16” (0.30 x 8 mm) in fixed needle	Nipro	SYMS-0.5U100-3008B-EC
Syringes U-100 1 mL with 26G x ½” (0.45 x 12.7 mm) in needle	PIC	20,71,26,03,00,354
Vet ointment for eyes	Lacrilube, Lacrigel Europhta
Xylazine	Rompun		This mixture of drug is used as injectable anaesthetic and sedative.
Zolazepam and Tiletamine	Zoletil 100		This drug is used as injectable anaesthetic, sedative, muscle relaxer, and analgesic

References

Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., Ciccarelli, O. Multiple sclerosis. Lancet. 391 (10130), 1622-1636 (2018).
Gold, S. M., Willing, A., Leypoldt, F., Paul, F., Friese, M. A. Sex differences in autoimmune disorders of the central nervous system. Semin immunopathol. 41 (2), 177-188 (2019).
Smith, P. Animal models of multiple sclerosis. Curr Protoc. 1 (6), 185 (2021).
Procaccini, C., De Rosa, V., Pucino, V., Formisano, L., Matarese, G. Animal models of Multiple Sclerosis. Eur J Pharmacol. 759, 182-191 (2015).
Torre-Fuentes, L., et al. Experimental models of demyelination and remyelination. Neurologia. 35 (1), 32-39 (2020).
Kipp, M., Nyamoya, S., Hochstrasser, T., Amor, S. Multiple sclerosis animal models: a clinical and histopathological perspective. Brain Pathol. 27 (2), 123-137 (2017).
Racke, M. K. Experimental autoimmune encephalomyelitis (EAE). Curr Protoc Neurosci. , (2001).
Constantinescu, C. S., Farooqi, N., O’Brien, K., Gran, B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 164 (4), 1079-1106 (2011).
Montarolo, F., Perga, S., Martire, S., Bertolotto, A. Nurr1 reduction influences the onset of chronic EAE in mice. Inflamm Res. 64 (11), 841-844 (2015).
Montarolo, F., et al. Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. PLoS One. 9 (9), 108791 (2014).
Furlan, C., et al. Analysis of the gadolinium retention in the experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis. J Trace Elem Med Biol. 68, 126831 (2021).
Desole, C., et al. Engineering, characterization, and biological evaluation of an antibody targeting the HGF receptor. Front Immunol. 12, 775151 (2021).
Voskuhl, R. R., MacKenzie-Graham, A. Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis. Front Mol Neurosci. 15, 1024058 (2022).
McCombe, P. A., Greer, J. M. Effects of biological sex and pregnancy in experimental autoimmune encephalomyelitis: It’s complicated. Front Immunol. 13, 1059833 (2022).
Ascherio, A., Munger, K. L. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. 36 (2), 103-114 (2016).
Spence, R. D., Voskuhl, R. R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol. 33 (1), 105-115 (2012).
Laffont, S., Garnier, L., Lélu, K., Guéry, J. -. C. Estrogen-mediated protection of experimental autoimmune encephalomyelitis: Lessons from the dissection of estrogen receptor-signaling in vivo. Biomed J. 38 (3), 194-205 (2015).
Avila, M., Bansal, A., Culberson, J., Peiris, A. N. The role of sex hormones in multiple sclerosis. Eur Neurol. 80 (1-2), 93-99 (2018).
Collongues, N., Patte-Mensah, C., De Seze, J., Mensah-Nyagan, A. -. G., Derfuss, T. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics. Expert Rev Neurother. 18 (6), 515-522 (2018).
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8 (6), 1000412 (2010).
Shaw, M. K., Zhao, X., Tse, H. Y. Overcoming unresponsiveness in experimental autoimmune encephalomyelitis (EAE) resistant mouse strains by adoptive transfer and antigenic challenge. J Vis Exp. (62), e3778 (2012).
Bittner, S., Afzali, A. M., Wiendl, H., Meuth, S. G. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Vis Exp. (86), (2014).
Downton, P., Early, J. O., Gibbs, J. E. Circadian rhythms in adaptive immunity. Immunology. 161 (4), 268-277 (2020).
McLean, A. C., Valenzuela, N., Fai, S., Bennett, S. A. L. Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp. (67), e4389 (2012).
Rahn, E. J., Iannitti, T., Donahue, R. R., Taylor, B. K. Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus. Biol Sex Differ. 5 (1), 4 (2014).
Bonaldo, B., et al. Effects of perinatal exposure to bisphenol A or S in EAE model of multiple sclerosis. Cell Tissue Res. 392 (2), 467-480 (2023).
vanden Berg, R., Laman, J. D., van Meurs, M., Hintzen, R. Q., Hoogenraad, C. C. Rotarod motor performance and advanced spinal cord lesion image analysis refine assessment of neurodegeneration in experimental autoimmune encephalomyelitis. J Neurosci Methods. 262, 66-76 (2016).
Bolton, C., Smith, P. Defining and regulating acute inflammatory lesion formation during the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. CNS Neurol Disord Drug Targets. 14 (7), 915-935 (2015).
Glaser, J. R., Glaser, E. M. Neuron imaging with Neurolucida–a PC-based system for image combining microscopy. Comput Med Imaging Graph. 14 (5), 307-317 (1990).
Kennedy, H. S., Puth, F., Van Hoy, M., Le Pichon, C. A method for removing the brain and spinal cord as one unit from adult mice and rats. Lab Anim (NY). 40 (2), 53-57 (2011).
Watson, C., Paxinos, G., Kayalioglu, G., Heise, C., Watson, C., Paxinos, G., Kayalioglu, G. Chapter 16 – Atlas of the mouse spinal cord. The Spinal. , 308-379 (2009).
Khan, A., et al. Suppression of TRPV1/TRPM8/P2Y nociceptors by withametelin via downregulating MAPK signaling in mouse model of vincristine-induced neuropathic pain. Int J Mol Sci. 22 (11), 6084 (2021).
Bergamaschi, R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 79, 423-447 (2007).
Harbo, H. F., et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens. 63 (3), 237-247 (2004).
Ryan, L., Mills, K. H. G. Sex differences regulate immune responses in experimental autoimmune encephalomyelitis and multiple sclerosis. Eur J Immunol. 52 (1), 24-33 (2022).
Lasrado, N., et al. Mechanisms of sex hormones in autoimmunity: focus on EAE. Biol Sex Differ. 11 (1), 50 (2020).
Hofstetter, H. H., Shive, C. L., Forsthuber, T. G. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol. 169 (1), 117-125 (2002).
Maria, Z., Turner, E., Agasing, A., Kumar, G., Axtell, R. C. Pertussis toxin inhibits encephalitogenic T-cell infiltration and promotes a B-cell-driven disease during Th17-EAE. Int J Mol Sci. 22 (6), 2924 (2021).
Krementsov, D. N., et al. Studies in experimental autoimmune encephalomyelitis do not support developmental bisphenol a exposure as an environmental factor in increasing multiple sclerosis risk. Toxicol Sci. 135 (1), 91-102 (2013).
Kummari, E., Nichols, J. M., Yang, E. -. J., Kaplan, B. L. F. Neuroinflammation and B-cell phenotypes in cervical and lumbosacral regions of the spinal cord in experimental autoimmune encephalomyelitis in the absence of pertussis toxin. Neuroimmunomodulation. 26 (4), 198-207 (2019).
Huntemann, N., et al. An optimized and validated protocol for inducing chronic experimental autoimmune encephalomyelitis in C57BL/6J mice. J Neurosci Methods. 367, 109443 (2022).

Play Video

PDF

DOI

DOWNLOAD MATERIALS LIST

Cite This Article

Bonaldo, B., Casile, A., Montarolo, F., Bertolotto, A. Modeling Multiple Sclerosis in the Two Sexes: MOG_35-55-Induced Experimental Autoimmune Encephalomyelitis. J. Vis. Exp. (200), e65778, doi:10.3791/65778 (2023).